1)   C10-041: Efficacy and Safety of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension plus Brimonidine 2 mg/mL Eye Drops, Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension.
 
2)   RESPOND: A Canadian 12 month, prospective, randomized, open label, multicenter, laser controlled phase III b study assessing the efficacy, safety and cost efficacy of Ranibizumab as combination and monotherapy in patients with impairment due to diabetic macular edema (DME).